This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IQVIA Holdings (IQV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 1.07% and 1.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Research Reports for Apple, Novo Nordisk & RTX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Novo Nordisk A/S (NVO) and RTX Corporation (RTX), as well as a micro-cap stock FONAR Corporation (FONR).
IQVIA Gears Up to Report Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
IQV's TAS and RD&S revenues are anticipated to have increased, while CSMS revenues are likely to have dipped in the third quarter of 2024.
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for IQVIA (IQV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EPAM Expands With First Derivative Buyout: What Should Investors Do?
by Zacks Equity Research
Epam Systems expands its AI capabilities in the financial space with the acquisition of First Derivative.
Here's Why You Should Retain IQVIA Holdings Shares Now
by Zacks Equity Research
While IQV benefits from its market leadership, data-driven innovation and global expansion, it must navigate pricing pressure.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQV Gains From Clinical Development Capabilities Amid Low Liquidity
by Zacks Equity Research
IQVIA's vast database, health-care-specific IT infrastructure and analytics-driven developments enable it to grow in the $300-billion market.
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top Analyst Reports for Amazon.com, Roche & GE Aerospace
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Roche Holding AG (RHHBY) and GE Aerospace (GE), as well as two micro-cap stocks Canterbury Park Holding Corporation (CPHC) and NVE Corporation (NVEC).
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain IQVIA (IQV) Stock for Now
by Zacks Equity Research
IQVIA (IQV) rides high on robust segmental performance, boosting the company's top line. However, elevated operating expenses and weak liquidity are a major concern.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Waste Connections (WCN) Marginally Dips Despite Q2 Earnings Beat
by Zacks Equity Research
Waste Connections (WCN) records improved segmental performances in the second quarter of 2024.
S&P Global (SPGI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
S&P Global's (SPGI) second-quarter 2024 earnings and revenues increase year over year.
Understanding IQVIA (IQV) Reliance on International Revenue
by Zacks Equity Research
Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Waste Management (WM) Q2 Earnings Meet Estimates, Rise Y/Y
by Zacks Equity Research
Waste Management's (WM) second-quarter 2024 earnings and revenues rise year over year.